PT100122A - Polipeptidos correspondentes aos locais de ligacao induzidos no receptor (ribs), anticorpos anti-ribs e processos de deteccao e de isolamento do anticorpo - Google Patents

Polipeptidos correspondentes aos locais de ligacao induzidos no receptor (ribs), anticorpos anti-ribs e processos de deteccao e de isolamento do anticorpo

Info

Publication number
PT100122A
PT100122A PT100122A PT10012292A PT100122A PT 100122 A PT100122 A PT 100122A PT 100122 A PT100122 A PT 100122A PT 10012292 A PT10012292 A PT 10012292A PT 100122 A PT100122 A PT 100122A
Authority
PT
Portugal
Prior art keywords
ribs
receptor
antibodies
ligand
induced
Prior art date
Application number
PT100122A
Other languages
English (en)
Other versions
PT100122B (pt
Inventor
Edward F Plow
Mark H Ginsberg
Concepcion Zamarron
Original Assignee
Scripps Research Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scripps Research Inst filed Critical Scripps Research Inst
Publication of PT100122A publication Critical patent/PT100122A/pt
Publication of PT100122B publication Critical patent/PT100122B/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/75—Fibrinogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G01N33/567—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds utilising isolate of tissue or organ as binding agent
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
PT100122A 1991-02-12 1992-02-12 Polipeptidos correspondentes aos locais de ligacao induzidos no receptor (ribs), anticorpos anti-ribs e processos de deteccao e de isolamento do anticorpo PT100122B (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/654,839 US5372933A (en) 1988-10-03 1991-02-12 Polypeptides that mimic receptor-induced binding sites, and methods of using same

Publications (2)

Publication Number Publication Date
PT100122A true PT100122A (pt) 1993-05-31
PT100122B PT100122B (pt) 1999-06-30

Family

ID=24626448

Family Applications (1)

Application Number Title Priority Date Filing Date
PT100122A PT100122B (pt) 1991-02-12 1992-02-12 Polipeptidos correspondentes aos locais de ligacao induzidos no receptor (ribs), anticorpos anti-ribs e processos de deteccao e de isolamento do anticorpo

Country Status (12)

Country Link
US (1) US5372933A (pt)
EP (1) EP0573545B1 (pt)
JP (2) JP3315405B2 (pt)
AT (1) ATE184019T1 (pt)
CA (1) CA2103893A1 (pt)
DE (1) DE69229911T2 (pt)
DK (1) DK0573545T3 (pt)
ES (1) ES2134799T3 (pt)
GR (1) GR3031720T3 (pt)
IE (1) IE920462A1 (pt)
PT (1) PT100122B (pt)
WO (1) WO1992014150A1 (pt)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6143298A (en) * 1988-09-01 2000-11-07 Bayer Corporation Soluble truncated forms of ICAM-1
US6051231A (en) * 1988-09-01 2000-04-18 Bayer Corporation Antiviral methods and prepations
US6514936B1 (en) 1988-09-01 2003-02-04 Bayer Corporation Antiviral methods using human rhinovirus receptor (ICAM-1)
EP0362531B1 (en) 1988-09-01 1999-11-10 Bayer Corporation A human rhinovirus receptor protein that inhibits virus infectivity
US6107461A (en) * 1990-07-20 2000-08-22 Bayer Corporation Multimeric forms of human rhinovirus receptor and fragments thereof, and method of use
DE69131564T2 (de) * 1990-07-20 2000-01-13 Bayer Corp., Pittsburgh Multimere Formen des menschlichen Rhinovirus-Rezeptorproteins
US6130202A (en) * 1990-07-20 2000-10-10 Bayer Corporation Antiviral methods
US5736122A (en) * 1991-02-08 1998-04-07 Diatide, Inc. Technetium-99m labeled peptides for thrombus imaging
EP0570493B1 (en) * 1991-02-08 2000-01-05 Diatide, Inc. TECHNETIUM-99m LABELED POLYPEPTIDES FOR IMAGING
US5645815A (en) 1991-02-08 1997-07-08 Diatide, Inc. Radiolabled compounds for thrombus imaging
US5968476A (en) * 1992-05-21 1999-10-19 Diatide, Inc. Technetium-99m labeled peptides for thrombus imaging
US6057287A (en) 1994-01-11 2000-05-02 Dyax Corp. Kallikrein-binding "Kunitz domain" proteins and analogues thereof
DE19620443C2 (de) * 1996-05-21 1998-09-17 Rhein Biotech Proz & Prod Gmbh Verfahren zum automatischen Durchführen von Bluttests
CA2312913A1 (en) 1997-12-12 1999-06-24 Jeffrey C. Way Compounds and methods for the inhibition of protein-protein interactions
US6623981B2 (en) 1998-01-27 2003-09-23 Bristol-Myers Squibb Company Detection of patients at risk for developing integrin antagonist/agonist mediated disease states
AU782233B2 (en) * 2000-01-20 2005-07-14 Hadasit Medical Research Services & Development Company Ltd Novel haptotactic peptides
EP1283899B1 (en) * 2000-05-24 2007-01-17 PH Plate Microplate Techniques AB New method and device
SE0001936D0 (sv) * 2000-05-24 2000-05-24 Phplate Stockholm Ab New method and device
US8143210B2 (en) 2002-02-14 2012-03-27 The Board Of Trustees Of The Leland Stanford Junior University Enzyme treatment of foodstuffs for celiac sprue
CA2475972C (en) * 2002-02-14 2017-07-11 Felix Hausch Enzyme treatment of foodstuffs for celiac sprue
US7462688B2 (en) * 2002-05-14 2008-12-09 The Board Of Trustees Of The Leland Stanford Junior University Peptides for diagnostic and therapeutic methods for celiac sprue
AU2003234634A1 (en) * 2002-05-14 2003-12-02 Felix Hausch Drug therapy for celiac sprue
US20040005612A1 (en) * 2002-05-14 2004-01-08 Giudice Linda C. Endometrial genes in endometrial disorders
US7265093B2 (en) * 2002-05-14 2007-09-04 The Board Of Trustees Of The Leland Stanford Junior University Drug therapy for Celiac Sprue
WO2003103475A2 (en) 2002-06-07 2003-12-18 Dyax Corp. Prevention and reduction of blood loss
US7153829B2 (en) * 2002-06-07 2006-12-26 Dyax Corp. Kallikrein-inhibitor therapies
SI2386310T1 (sl) 2002-08-28 2019-03-29 Dyax Corp. Metode za ohranjanje organov in tkiv
IL152609A0 (en) * 2002-11-03 2003-06-24 Hapto Biotech Inc Liposomal compositions comprising haptotactic peptides and uses thereof
DK1563300T3 (da) * 2002-11-20 2012-07-23 Univ Leland Stanford Junior Diagnostisk fremgangsmåde til cøliaki
US7579313B2 (en) * 2003-11-18 2009-08-25 The Board Of Trustees Of The Leland Stanford Junior University Transglutaminase inhibitors and methods of use thereof
WO2005066202A2 (en) * 2003-12-22 2005-07-21 E.I. Du Pont De Nemours And Company Bacillus cry9 family members
US7235530B2 (en) * 2004-09-27 2007-06-26 Dyax Corporation Kallikrein inhibitors and anti-thrombolytic agents and uses thereof
US7807645B2 (en) * 2005-09-23 2010-10-05 The Regents Of The University Of California Method of treating degenerative disorders of the nervous system by administration of fibrinogen fragment
CA2643693A1 (en) * 2006-03-10 2007-09-20 Dyax Corp. Formulations for ecallantide
EP2136833B1 (en) * 2007-03-16 2019-05-01 The Board of Trustees of the Leland Stanford Junior University Combination enzyme therapy for digestion of dietary gluten
CN102307594A (zh) * 2009-01-06 2012-01-04 戴埃克斯有限公司 用激肽释放酶抑制剂治疗粘膜炎
HUE039605T2 (hu) 2010-01-06 2019-01-28 Dyax Corp Plazma kallikreint kötõ proteinek
ES2545749T3 (es) 2010-02-22 2015-09-15 B Food Science Co., Ltd. Potenciador de la adhesión célula-célula epitelial para uso en la mejora, tratamiento y prevención de enfermedades alérgicas
KR102320178B1 (ko) 2011-01-06 2021-11-02 다케다 파머수티컬 컴패니 리미티드 혈장 칼리크레인 결합 단백질
WO2015148790A1 (en) 2014-03-27 2015-10-01 Dyax Corp. Compositions and methods for treatment of diabetic macular edema
NZ744233A (en) 2015-12-11 2023-11-24 Takeda Pharmaceuticals Co Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack
EP3715375A1 (en) 2019-03-23 2020-09-30 Ablevia biotech GmbH Compound for the prevention or treatment of pre-eclampsia
EP3715376A1 (en) 2019-03-23 2020-09-30 Ablevia biotech GmbH Compound for the prevention or treatment of myasthenia gravis
US11986536B2 (en) 2019-03-23 2024-05-21 Ablevia Biotech Gmbh Compound for the sequestration of undesirable antibodies in a patient
EP3715374A1 (en) 2019-03-23 2020-09-30 Ablevia biotech GmbH Compound for the sequestration of undesirable antibodies in a patient
IL301332A (en) 2020-09-23 2023-05-01 Ablevia Biotech Gmbh A compound for preventing or treating conditions mediated by autoantibodies
TW202228784A (zh) 2020-09-23 2022-08-01 奧地利商艾柏力維亞生技有限公司 用以於一患者中螯合非預期的抗ｐｅｇ抗體的化合物
US20230365655A1 (en) 2020-09-23 2023-11-16 Ablevia Biotech Gmbh Compound for increasing the efficacy of factor viii replacement therapy
US20230381334A1 (en) 2020-09-23 2023-11-30 Ablevia Biotech Gmbh Compound for the sequestration of undesirable antibodies in a patient
US20230355747A1 (en) 2020-09-23 2023-11-09 Ablevia Biotech Gmbh Compound for increasing efficacy of viral vectors
CN116710143A (zh) 2020-09-24 2023-09-05 艾柏力维亚生技有限公司 用于预防或治疗重症肌无力的化合物
WO2023180502A1 (en) 2022-03-24 2023-09-28 Ablevia Biotech Gmbh Compound for increasing efficacy of oncolytic viruses

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4455290A (en) * 1981-04-02 1984-06-19 Research Corporation Inhibition of fibrin polymerization by a peptide isolated from fibrin Fragment D1
DE3364347D1 (en) * 1982-04-09 1986-08-07 Fujirebio Kk Anti immune complex antibody and preparation thereof
GB2161165A (en) * 1984-06-12 1986-01-08 Cambridge Patent Dev Secondary antibodies
US4820505A (en) * 1985-04-04 1989-04-11 Scripps Clinic And Research Foundation Detection of activated platelets with antibodies to thrombospondin
ATE188248T1 (de) * 1988-10-03 2000-01-15 Scripps Research Inst Monoklonale antikörper gegen rezeptor-induzierte bindungsstellen auf liganden, die an proteine der cytoadhesin-superfamilie binden

Also Published As

Publication number Publication date
WO1992014150A1 (en) 1992-08-20
GR3031720T3 (en) 2000-02-29
PT100122B (pt) 1999-06-30
JP2002275196A (ja) 2002-09-25
US5372933A (en) 1994-12-13
JPH06506203A (ja) 1994-07-14
AU1415292A (en) 1992-09-07
DE69229911D1 (de) 1999-10-07
ATE184019T1 (de) 1999-09-15
EP0573545A4 (en) 1995-04-12
DE69229911T2 (de) 2000-01-20
EP0573545B1 (en) 1999-09-01
IE920462A1 (en) 1992-08-12
ES2134799T3 (es) 1999-10-16
JP3315405B2 (ja) 2002-08-19
DK0573545T3 (da) 1999-12-13
EP0573545A1 (en) 1993-12-15
CA2103893A1 (en) 1992-08-13
AU649800B2 (en) 1994-06-02

Similar Documents

Publication Publication Date Title
PT100122A (pt) Polipeptidos correspondentes aos locais de ligacao induzidos no receptor (ribs), anticorpos anti-ribs e processos de deteccao e de isolamento do anticorpo
CA2047717A1 (en) Monoclonal antibodies for small moieties, methods therefor
ES8607564A1 (es) Un metodo para determinar la presencia de un determinante antigenico de interleuquina-2-en una muestra.
ES2013328A6 (es) Un metodo para detectar anticuerpos contra antigenos hiv-1.
NO20001668L (no) Anvendelse av et DNA-fragment, samt komplementære kjeder, derivater og deler derav
ES8802457A1 (es) Un procedimiento para la preparacion de polipeptidos inmunogenicos
NO172596C (no) Apolipoprotein b-spesifikke monoklonale antistoffer produsert av to nye hybridomer, anvendelse av disse og diagnostiske systemer inneholdende disse
GR3031607T3 (en) Selective system scan for multizone radiotelephone subscriber units.
DE3268740D1 (en) Rapid, quantitative peptide synthesis using mixed anhydrides
EP0167596A4 (en) ANTI-IDIOTYPIC ANTIBODIES INDUCED BY SYNTHETIC POLYPEPTIDES.
DE3586808D1 (de) L-thyroxin erkennende monoklonale antikoerper.
GR1002145B (en) Monoclonal antibodies against receptor - induced binding sites
NO173831C (no) Nye monoklonale antistoffer mot IFN-omega, hybridomer til fremstilling derav og anvendelse for rensing samt paavisning eller kvantitativ bestemmelse av IFN-omega, og sett for bruk ved paavisningen
ATE180788T1 (de) Polypeptide mit einer aktivität des menschlichen dopaminergischen rezeptors, deren kodierende nukleinsäuresequenzen und verwendung dieser polypeptide
DK414386A (da) Monoklonalt antistof, cellelinje til fremstilling deraf og antistoffets anvendelse
DE68917797D1 (de) Gegen menschliches Fibrinopepid A spezifische monoklonale Antikörper.
FI101808B1 (fi) Monoklonaaliset vasta-aineet reseptori-indusoituja sitoutumiskohtia vastaan
DK302785A (da) Monoklonale antistoffer overfor humant interferon-gamma, hybridcellelinier, der frembringer disse antistoffer, antistoffernes anvendelse og fremgangsmaader til fremstilling deraf
NZ228194A (en) Monoclonal antibodies which bind to the n-terminal peptide sequence of the betasubunit of human haemoglobiin
HU9300054D0 (en) Developing elisa test based on monoclonal antibodies to detect infection by m. gallisepticum
NO874798D0 (no) Fremgangsmaate for fremstilling av monoklonale antistoffer ved dyrking av hybridom-cellelinjen lym-1.
KR920009979A (ko) 프로제스테론 홀몬의 특이항체 분비 세포주

Legal Events

Date Code Title Description
BB1A Laying open of patent application

Effective date: 19921222

FG3A Patent granted, date of granting

Effective date: 19990322

MM4A Annulment/lapse due to non-payment of fees, searched and examined patent

Free format text: LAPSE DUE TO NON-PAYMENT OF FEES

Effective date: 20070924